A Decade of Progress in Myeloma, And More to Come

New treatments and research are giving patients a reason to be hopeful for today and tomorrow

As Multiple Myeloma Awareness Month comes around again, the myeloma community has good reason to celebrate the past decade, which has brought new treatment options for today and a better understanding of how to treat this disease in the future.

A patient who is diagnosed with myeloma has an about 47 percent chance of living five years or longer, which is up from 31 percent twelve years earlier.1 Meanwhile, although people are being diagnosed with myeloma at an increasing rate each year, their survival chances are improving.2

“The progress has been quite dramatic,” Dr. Paul G. Richardson of the Dana-Farber Cancer Institute Hematology Oncology department said. “Although we may have seen similar improvements in other cancers, the difference with myeloma has really been the volume of new treatment options that have been approved in the past decade and their impact on outcomes as reflected by the improvements we have seen in survival.”3

Between 2006 and 2015, the U.S. Food and Drug Administration approved 13 new therapies for the treatment of myeloma, which is especially remarkable considering myeloma accounts for less than 2 percent of new cancer cases in the United States each year.4 During the same period, the FDA approved 20 treatments for lung cancer, which accounts for 13 percent of all new cancer cases, and 12 for breast cancer, which accounts for 12 percent.5,6

A Decade of Progress in Myeloma infographic7

These new myeloma therapies have already helped patients live longer lives,8 and the best may be yet to come as doctors explore how to use them most effectively. According to data released during the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), researchers believe that by 2022 at least half of myeloma patients will live 6 years after being diagnosed, which is 140 percent longer than was expected in 2001.9

Over the past decade, researchers have improved our understanding of the immune system’s role in myeloma, which may transform the way we treat this cancer in the future. For instance, one study of 74 myeloma patients who live for 10 years or longer found that their immune systems may be better equipped to recognize and attack harmful entities—such as cancer cells—than others.10

Over the next decade, immunotherapies, which leverage our body’s immune system to bring cancer under control, may help further extend the lives of myeloma patients. These approaches include antibody-based therapies, chimeric antigen receptor (CAR) T-cells and checkpoint inhibitors.11

“While immunotherapies are certainly exciting because of their new approaches, we should not underestimate the therapies approved over the past decade,” Richardson said. “There’s going to be great value in combining the next generation of myeloma therapies with those we have today.”12

To learn more about how myeloma treatments are allowing patients to continue living active lifestyles, read our “Patients Not Letting Myeloma Hold Them Back” story.



1 SEER Stat Fact Sheets: Myeloma. Surveillance, Epidemiology and End Results Program. National Cancer Institute.  http://seer.cancer.gov/statfacts/html/mulmy.html Screenshots: http://screencast.com/t/Ea3yiG6aSU, http://screencast.com/t/8HWfLIqGON Accessed February 26, 2016.

2 SEER Stat Fact Sheets: Myeloma. Surveillance, Epidemiology and End Results Program. National Cancer Institute.  http://seer.cancer.gov/statfacts/html/mulmy.html Accessed February 26, 2016.

3 Interview with Paul G. Richardson, Dana-Farber Cancer Institute, Screenshot: http://screencast.com/t/7NvOKt14KL9 February 2016.

4 Cancer facts & figures 2016. American Cancer Society. 2016. http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf Accessed March 17, 2016.

5 Hematology/Oncology (Cancer) Approvals & Safety Notifications. U.S. Food and Drug Administration. 2016. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm Accessed February 26, 2016.

6 Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.1, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2014. http://globocan.iarc.fr. Accessed March 1, 2016.

7 SEER Stat Fact Sheets: Myeloma. Surveillance, Epidemiology and End Results Program. National Cancer Institute.  http://seer.cancer.gov/statfacts/html/mulmy.html Screenshots: http://screencast.com/t/2ounTtrHsal Accessed February 26, 2016.

8 Kumar S. K., Dispenzieri A., Lacy M. Q., et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122-1128. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000285/ Accessed February 26, 2016.

9 Drawid A, et al. Impact of novel therapies on multiple myeloma survival in the US: Current and future outcomes. http://meetinglibrary.asco.org/content/152003-156 Accessed February 26, 2016.

10 Magalhães Roberto J., Vidriales María-Belén B., Paiva Bruno, et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica. 2013;98:79-86. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533663/ Accessed February 26, 2016.

11 Ayed Ayed O., Chang Lung-Ji J., Moreb Jan S. Immunotherapy for multiple myeloma: Current status and future directions. Critical reviews in oncology/hematology. 2015;96:399-412. http://www.ncbi.nlm.nih.gov/pubmed/26153389 Accessed February 26, 2016.

12 Interview with Paul G. Richardson, Dana-Farber Cancer Institute, February 2016.